Group 1: Financial Performance - In 2024, the company's raw material drug exports achieved sales revenue of 63.39 million yuan, a year-on-year increase of 155.71% [2] - The net profit for Q1 2025 reached 44.50 million yuan, representing a year-on-year growth of 371.23% [5] - The export revenue for Q1 2025 decreased by 10.92% compared to Q4 2024 [7] Group 2: Product Development and Market Strategy - The company is focusing on increasing investment in pet drug research and market channel development, with a complete product matrix already established [3] - The Vietnam production base has a designed capacity of 1,500 tons per year, primarily producing chemical drug formulations [4] - The company is actively exploring overseas markets and implementing a "go out" strategy to mitigate domestic business cycle impacts [5] Group 3: Market Position and Competitive Strategy - The pet segment currently has a small revenue share but is showing a good growth trend [3] - The company is enhancing its competitive edge by deepening the integration of raw materials and formulations, optimizing product performance, and improving the industry chain structure [7] - The company does not currently engage in the pet hospital and vaccine business but is monitoring the market for potential opportunities [6]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

武汉回盛生物科技股份有限公司 关于子公司获得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，经中华人民共和国农 业农村部（以下简称"农业农村部"）审查，批准武汉回盛生物科技股份有限 公司（以下简称"公司"）子公司湖北回盛生物科技有限公司与其他单位联合 申报的"四季青提取散"为新兽药，农业农村部于 2025 年 6 月 9 日核发了《新 兽药注册证书》（农业农村部公告第 917 号），具体情况如下： 一、新兽药的基本信息 新兽药名称：四季青提取散 研制单位：青岛上药科技有限公司、瑞普（天津）生物药业有限公司、青 岛润达生物科技有限公司、艾美科健（中国）生物医药有限公司、湖南加农正 和生物技术有限公司、青岛信诺邦生物科技有限公司、湖北回盛生物科技有限 公司、山东鑫谷健康产业有限公司、江西嘉博生物工程有限公司、青岛大学 类别：三类 证券代码：300871 证券简称：回盛生物 公告编号：2025-064 二、该兽药产品研发及相关市场背景情况 全面禁抗后，饲料中禁止使用抗生素，对于养殖户而言，在短期内会 ...

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

证券代码：300871 证券简称：回盛生物 公告编号：2025-063 武汉回盛生物科技股份有限公司 关于完成注册资本变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 28 日召开第三届董事会第二十二次会议，于 2025 年 5 月 20 日召开 2024 年年度股东大会，审议通过了《关于变更注册资本暨修改<公司章程>的议案》， 在 2024 年 8 月 1 日至 2025 年 4 月 10 日期间，因"回盛转债"持有人行使转 股权，公司总股本由 165,764,170 股变更为 179,194,432 股，同意将公司注册资 本由 165,764,170 元变更为 179,194,432 元，同时修订《公司章程》相应条款。 具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网发布的《关于变更注册资 本暨修改<公司章程>的公告》（公告编号：2025-039）。 近日，公司完成工商变更登记手续，并取得了武汉市市场监督管理局换发 的《营业执照》，公司新 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 关于"回盛转债"赎回结果的公告 一、可转换公司债券基本情况 （一）可转债发行上市情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意武汉 回盛生物科技股份有限公司向不特定对象发行可转换公司债券注册的批复》 （证监许可〔2021〕3570 号）同意注册，武汉回盛生物科技股份有限公司（以 下简称"公司"）于 2021 年 12 月 17 日向不特定对象发行了 700 万张可转换 公司债券（以下简称"可转债"），每张面值为 100 元，发行总额 70,000 万 元，期限为 6 年。 经深圳证券交易所（以下简称"深交所"）同意，公司 70,000 万元可转 债于 2022 年 1 月 7 日起在深交所挂牌交易，债券简称"回盛转债"，债券代 码"123132"。 （二）可转债转股期限 根据《武 ...

| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2025-062 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 关于"回盛转债"摘牌的公告 （一）可转债发行上市情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"回盛转债"赎回日：2025 年 5 月 21 日 2、投资者赎回款到账日：2025 年 5 月 28 日 3、"回盛转债"摘牌日：2025 年 5 月 29 日 4、"回盛转债"摘牌原因：存续期内可转债全部赎回 一、可转换公司债券基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意武汉 回盛生物科技股份有限公司向不特定对象发行可转换公司债券注册的批复》 （证监许可〔2021〕3570 号）同意注册，武汉回盛生物科技股份有限公司（以 下简称"公司"）于 2021 年 12 月 17 日向不特定对象发行了 700 万张可转换 公司债券（以下简称"可转债"），每张面值为 100 元，发行总额 70,000 万 元，期 ...

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

2021年12月31日，回盛生物发布的创业板向不特定对象发行可转换公司债券上市公告书显示，本次发行 可转换公司债券募集资金总额为70,000.00万元(含发行费用)，扣除不含税发行费用的募集资金净额为 68,929.90万元。本次发行可转换公司债券募集资金扣除承销及保荐费855.66万元(不含税)的余额 69,144.34万元已由保荐机构(主承销商)于2021年12月23日汇入公司指定的募集资金专项存储账户中审众 环会计师事务所(特殊普通合伙)已进行验证，并出具了"众环验字(2021)0100097号"《验证报告》。回盛 生物此次的保荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代 表人为陈禹安、吴逸。 回盛生物于2020年8月24日在科创板上市，发行数量为2770万股，发行价格33.61元/股，保荐机构(主承 销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为张若思、金涛。 经计算，回盛生物上述两次募资共计16.31亿元。 中国经济网北京5月28日讯回盛生物（300871）(300871.SZ)近日披露2025年第一季度报告，报告期内， 该公司 ...

Group 1 - The pet economy concept is experiencing significant downturns, with Tianyuan Pet (301335) and Meinong Bio (301156) opening lower and declining nearly 10% [1] - Other companies such as Yuanfei Pet (001222), Daqian Ecology (603955), Huisheng Bio (300871), and Lusi Co. are also seeing notable declines [1] - There is a stealthy inflow of dark pool funds into these stocks, indicating potential interest despite the current market conditions [1]